Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Veru Inc.

VERU

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Last trade $2.15
Day change +$0.07 (+3.37%)
Day range $2.02 – $2.19
Volume 244,444
Market cap $35M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$35.46M
Price / earnings
—
Price / book
1.25×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.42×

Profitability

Earnings per share
-$0.80
Return on assets
-36.75%
Return on equity
-47.96%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.42×
Quick ratio
4.42×
Cash ratio
3.88×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$26.04M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VERU, quarterly periods
Line itemQ3 FY2026 Jun 30, 2026Q2 FY2026 Mar 31, 2026Q1 FY2026 Dec 31, 2025Q4 FY2025 Sep 30, 2025Q3 FY2025 Jun 30, 2025Q2 FY2025 Mar 31, 2025Q1 FY2025 Dec 31, 2024Q4 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$3.36M$4.07M$4.08M$4.54M$5.01M$5.16M$5.23M$6.25M
Research and development$4.35M$3.15M$1.34M$2.92M$3.02M$3.93M$5.72M$3.29M
Total operating expenses$7.71M$7.22M$5.42M$7.46M$8.03M$9.1M$10.94M$9.54M
Operating income-$7.71M-$7.22M-$5.42M-$7.46M-$8.03M-$9.1M-$10.94M-$9.54M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$6.99M-$3.09M-$5.33M$1.3M-$7.32M-$7.85M-$1.81M-$8.55M
Income taxes$0$0$0$0$0$0$0$0
Net income-$6.99M-$2.74M-$5.33M$1.45M-$7.33M-$7.9M-$8.95M-$8.53M
Net income attributable to common shareholders-$6.99M-$2.74M-$5.33M$1.45M-$7.33M-$7.9M-$8.95M-$8.53M
EBITDA-$7.69M-$7.19M-$5.4M-$7.43M-$8M-$9.07M-$10.88M-$9.47M
Basic earnings per share-$0.30-$0.12-$0.26$0.10-$0.50-$0.54-$0.61-$0.58
Diluted earnings per share-$0.30-$0.12-$0.26$0.10-$0.50-$0.54-$0.61-$0.58

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Veru Inc. has sold its FC2 Female Condom business for $18 million, allowing the company to focus on its late-stage biopharmaceutical pipeline, including a Phase 2b clinical trial evaluating enobosarm to preserve muscle and augment fat loss in patients receiving the GLP-1 receptor agonist Wegovy.

GlobeNewswire Inc.

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced the company will be participating in the Leerink Therapeutics Forum: I&I and Metabolism on July 9th, 2024, in Boston, Massachusetts.

GlobeNewswire Inc.

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from two late-breaker presentations at the American Diabetes Association's 84th Scientific Sessions, which took place on June 21-24, 2024, in Orlando, Florida.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Apr 28, 2014$0.70May 7, 2014recurring
Jan 27, 2014$0.70Feb 5, 2014recurring
Oct 28, 2013$0.70Nov 6, 2013recurring
Jul 29, 2013$0.70Aug 7, 2013recurring
Apr 29, 2013$0.70May 8, 2013recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 11, 20251-for-10reverse split